藍帆醫療(002382.SZ):藍帆新材料和藍帆(上海)擬新增銀行授信1.25億元
格隆匯3月17日丨藍帆醫療(002382.SZ)公佈,基於公司和子公司山東藍帆新材料有限公司(“藍帆新材料”)被列入全國疫情防控重點保障企業名單,子公司藍帆(上海)貿易有限公司(“藍帆(上海)”)是上海市重點疫情防控所需物資供應單位,為積極響應防控新型冠狀病毒感染的肺炎疫情需要,同時結合子公司2020年生產經營及發展情況,部分商業銀行擬新增為藍帆新材料和藍帆(上海)提供綜合授信額度共計1.25億元,2020年子公司將根據實際生產經營需要適時向各銀行申請貸款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.